Keywords: isis, shows, efficacy, crohn, pharmaceuticals, presented, promising

ISIS 2302 Shows Efficacy In Crohn's

Article | 10 March 1997

Isis Pharmaceuticals has presented promising Phase II data which showthat its antisense anti-inflammatory drug ISIS 2302 is safe and effective in ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Isis Pharmaceuticals

Boehringer Ingelheim

Go to company listing